NCT03465059View on ClinicalTrials.gov

Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

May 30, 2018

Primary Completion Date

October 19, 2018

Study Completion Date

October 19, 2018

Conditions
Hepatic Insufficiency & Healthy Subjects
Interventions
DRUG

Zanubrutinib

A single oral dose of 80 mg Zanubrutinib will be administered.

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

33124

University of Miami, Miami

Sponsors

Lead Sponsor

BeiGene
All Listed Sponsors
lead

BeiGene

INDUSTRY